|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
MejoraCare-Paraguay main objective is to test a mHealth solution (MejoraCare app) to be used for the education and empowerment of chronic patients (COPD, cancer, diabetes, heart disease. hypertension, etc.), and for supporting healthcare professionals to monitor and better understand patients' evolution during the COVID-19 outbreak (MejoraCare dashboard). This mHealth solution is built upon the Adhera platform developed by Salumedia Labs, which has already been validated in other therapeutic areas such as smoking cessation. MejoraCare is expected to raise awareness, educate and empower chronic patients, promoting behavioral changes towards adhering to healthier lifestyles thus reducing the risk of COVID-19 infection while providing emotional regulation support aiming at improving their mental health, quality of life, and emotional well-being.
Description: The Health-related Quality of Life will be measured through the EuroQoL-5D-3L questionnaire measures health related quality of life. The questionnaire consist of five dimensions: mobility, self care, ordinary activities, discomfort, and mood state related to anxiety and depression. Each item ranges form no problem to a lot of problems.Measure: Change on Health-related Quality of Life Time: Baseline, 1, and 3, 6 and 12 months
Description: Usability of the MejoraCare app will be measured through the SUS questionnaire at the end of the study. This questionnaire will only be completed by patients allocated to intervention group, and gives a global view on the subjective assessment of usability of a technology systemMeasure: MejoraCare app Usability Time: 1 month
Description: Satisfaction with the MejoraCare app will be measured through the CSQ questionnaire at the end of the study. This questionnaire will only be completed by patients allocated to the intervention group. This questionnaire is used to measure global patient satisfactionMeasure: Satisfaction with the MejoraCare app Time: 1 month
Description: Change in Self-efficacy will be measured through the GSES-12 questionnaire. The scale is composed of 12 items and has 3 factors: Initiative (willingness to initiate behavior), Effort (willingness to make an effort to complete the behavior), and Persistence (persevering to complete the task in the face of adversity).Measure: Change in Self-efficacy Time: Baseline, 1, 3, 6 and 12 months
Description: Change in anxiety will be measured through the GAD-2 questionnaire. The Generalized Anxiety Disorder Questionnaire-2 (GAD-2; Kroenke et al., 2007; García-Campayo et al., 2012) is a 2-item self-report that can be used to screen and detect symptoms of anxiety.Measure: Change in Anxiety Time: Baseline, 1, 3, 6 and 12 months
Description: Change in depression will be measured through the PHQ-2 questionnaire. The Patient Health Questionnaire-2 (PHQ-2; Kroenke et al., 2003; Rodríguez-Muñoz et al., 2017) is a 2-item self-report questionnaire that is used to screen and detect depressive symptomatology. Items responses are rated on a 4-point Likert-scale (0 = not at all, 3 = nearly every day).Measure: Change in Depression Time: Baseline, 1, 3, 6 and 12 months
Description: Change in empowerment will be measured through the EAS questionnaire. The scale measures the degree of empowerment in health-care, assessing self-control, self-efficacy, problem-solving, psychosocial coping, support, motivation, and decision-makingMeasure: Change in Health Empowerment Time: Baseline, 1, 3, 6 and 12 months
Description: Change in coping will be measured through the PSS-4 questionnaire. The short version, PSS-4, is an economical and simple psychological instrument to administer, comprehend, and score. It measures the degree to which situations in one's life over the past month are appraised as stressful.Measure: Change in Coping with Stress Time: Baseline, 1, 3, 6 and 12 months
Description: It is an ad-hoc scale design to asses the prior knowledge/skill of participants in the use of common technologies as mobiles phones or the computer. The scale has 9 items that score independently in a scale ranging from 0 to 4. Higher scores are associated with a better knowledge in the use of technologiesMeasure: Technological profile Time: Baseline
Description: It is an scale for assess the usability of mHealth applications. The scale has 26 items rated on a 7-point Likert-scale (1 = totally disagree, 7 = totally agree). Higher scores are related to a better opinion regarding the mobile applicationMeasure: mHealth App Usability Questionnaire Time: 1 month
Description: It is an scale for assess the utility of mHealth applications. The scale has 16 items rated on a 7-point Likert-scale (1 = totally disagree, 7 = totally agree). Higher scores are related to a better experience regarding the mobile applicationMeasure: Telehealth Questionnaire (TUQ) Time: 1 month
Description: It is a scale to assess the openness of the participant to use technologies in their daily life. The scale has 7 items rated on a 5-point Likert-scale (1 = totally disagree, 5 = totally agree). Higher scores are related to a higher comodity in the use of technologiesMeasure: COMPUTER FLUENCY SCALE (CFS) Time: Baseline
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports